Live
- GAIL clocks net profit of Rs 2,672 crore in Q2
- Sr Men's National Hockey: Delhi, Karnataka, Bengal, A.P. win group matches on Day 2
- ‘Nation is proud of you’: West Bengal Guv to GRSE on laying keels of two NGOPVS
- Kirttane, Kapadia bag golden double as India wins 14 medals in Asia Pickleball Games
- Gurugram: 11 projects of GMDA worth Rs 249.77 crores approved
- Akali Dal stages statewide protests over ‘tardy’ paddy procurement in Punjab
- Firing on Nandan Kanan Express in Odisha, probe launched
- Indian Army Seizes Massive Cache Of Arms And Ammunition In Manipur Amid Ongoing Violence
- Polling Stations Open Across Eastern And Central US As Voters Head To The Ballots In Historic Election
- Hyatt set to expand brand presence in Nepal with hyatt regency lumbini
India could get access to AstraZeneca vaccine by January, says local manufacturer
AstraZeneca vaccine
The head of an Indian company contracted to make AstraZeneca Plc's Covid vaccine said it could deliver it to health care workers and elderly Indians by January as the country's caseload of infections crossed nine million on Friday.
MUMBAI: The head of an Indian company contracted to make AstraZeneca Plc's Covid vaccine said it could deliver it to health care workers and elderly Indians by January as the country's caseload of infections crossed nine million on Friday.
The Serum Institute of India, the world's largest vaccine manufacturer, has already manufactured millions of doses of the vaccine that is being developed in collaboration with Oxford University while results from late-stage trials are awaited.
Britain-based AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world.
On Thursday, data published in the medical journal The Lancet showed that AstraZeneca's vaccine produced a strong immune response in older adults, with researchers expecting to release late-stage trial results by Christmas.
Drugmakers Pfizer Inc and Moderna Inc have also released data from late-stage trials that shows more than 90% efficacy in their vaccine candidates.
India is watching the progress of the Pfizer and Moderna vaccines, but availability and supply could be an issue with a population as large as India's, the head of a committee advising the prime minister said this week.
Adar Poonawaala, the chief executive of the SII, said that his company would seek emergency use authorisation for the AstraZeneca vaccine as soon as authorities in the United Kingdom approved it and made it available for the general public.
"It's been a Herculean task and we are very happy now that we are almost now on autopilot waiting just for the vaccine results to come," Poonawaala told a conference on Thursday. "Then we can churn out hundreds of millions more of the vaccine."
The vaccine would be priced between $5-$6 in the retail market, but the Indian government would get it for much less, because they would buy it bulk, Poonawaala said.
It would take at least two to three years for all of India's 1.3 billion population to be covered, he said.
India has the world's second-highest number of infections, after the United States, but cases have slowed down since hitting a peak in September.
It recorded 45,882 new infections and 584 deaths in the last 24 hours, the health ministry said on Friday. India has now registered more than nine million cases of the coronavirus and 132,162 deaths.
An Indian government-backed vaccine, developed by private company Bharat Biotech, could be launched as early as February, a government scientist told Reuters earlier this month.
